Research
Hormonal
Fibro-inflammatory progenitors (FIPs) in adipose tissue are anti-adipogenic and promote inflammation and fibrosis, contributing to unhealthy adipose remodeling.
Chronic inflammation in fat tissue can be driven by specific cell types (FIPs) that block healthy fat storage. Managing inflammation through diet and exercise may help reduce the activity of these anti-adipogenic cells, allowing for healthier fat tissue expansion.
GoodRefutesHIGH confidence
LY6C+PDGFRβ+ cells... we refer to these cells as fibro-inflammatory progenitors (FIPs)... FIPs are also functionally anti-adipogenic and can inhibit differentiation of APCs in vitro through the production of unknown secreted factors.
Why this rating
Based on single-cell RNA sequencing and functional in vitro studies in mice.
Source
Contribution of adipogenesis to healthy adipose tissue expansion in obesity
Lavanya Vishvanath et al. · Journal of Clinical Investigation · 2019
DOI 10.1172/jci129191
narrative_reviewCited 535×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Subcutaneous white adipose tissue (WAT) expansion is metabolically protective, whereas preferential visceral WAT expansion is associated with increased risk for insulin resistance and metabolic syndrome.Strong
- Stimulating de novo adipogenesis (adipocyte hyperplasia) in visceral white adipose tissue during caloric excess drives healthy tissue remodeling, maintaining insulin sensitivity and preventing metabolic syndrome.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →